Repligen (RGEN)
(Real Time Quote from BATS)
$157.08 USD
-4.59 (-2.84%)
Updated Aug 5, 2024 10:06 AM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
Repligen Corporation [RGEN]
Reports for Purchase
Showing records 61 - 80 ( 208 total )
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
JPM Takeaways, Positive Industry Backdrop for 2023
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Healthcare: Life Sciences Tools & Services
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Gene Therapy Significant in Our New FY23-FY25 Estimates
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
3Q22 - Early 2023 Parameters Seem Typically Conservative
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Life Sciences: COVID Era Concluding - Mapping Company Exposure
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
DHR & SRT3: Strong Life Science Earnings Season Begins
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
2Q Preview - Mapping COVID Sales; 2023 Visibility Increasing
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department